Amgen's IMDYLLTRA Gains EU Approval for Extensive-Stage Small Cell Lung Cancer — Amgen Inc.

Event summary

European Commission approves Amgen's IMDYLLTRA (tarlatamab) for extensive-stage small cell lung cancer (ES-SCLC) on June 1, 2026.
Approval based on Phase 3 DeLLphi-304 trial showing 40% reduction in risk of death and median overall survival extended by over five months.
IMDYLLTRA is the first and only T-cell engager therapy approved for SCLC in Europe.
Common adverse reactions include cytokine release syndrome (56.7%), decreased appetite (36.4%), and pyrexia (31.9%).
Amgen's clinical development program includes multiple ongoing trials evaluating IMDYLLTRA in various combinations and settings.

The big picture

Amgen's IMDYLLTRA approval marks a significant milestone in the treatment of extensive-stage small cell lung cancer, a disease with high relapse rates and limited options. The approval underscores the growing importance of T-cell engager therapies in oncology, reflecting broader industry trends toward targeted immunotherapies. With a global Phase 3 trial demonstrating substantial survival benefits, IMDYLLTRA positions Amgen to capture a larger share of the SCLC market, potentially reshaping treatment paradigms for this aggressive cancer.

What we're watching

Clinical Development: The pace at which Amgen advances its robust IMDYLLTRA clinical development program, including combination regimens and earlier lines of treatment.
Market Penetration: How IMDYLLTRA's approval will impact Amgen's market share in the SCLC treatment landscape and its competitive positioning against existing therapies.
Regulatory Dynamics: Whether the positive results from the DeLLphi-304 trial will facilitate expedited approvals in other major markets, such as the U.S.